HASBROUCK HEIGHTS, N.J., August 21 /CNW/ - Nymox Pharmaceutical
Corporation (NASDAQ: NYMX) today announced that further clinical results from
the Company's studies of NX-1207 for benign prostatic hyperplasia (BPH) will
be presented at the meeting of the Western Section of the American Urological
Association (AUA) to be held in Scottsdale, Arizona in October. The paper is
authored by leading clinical research investigators from U.S. clinical trials
of NX-1207. Further specific details on the upcoming presentation will be
announced at a later date.
